Genmab Shares Jump 30% as Head and Neck Cancer Combo Cuts Death Risk by Half
Genmab (GMAB) shares surged 30% after its experimental antibody petosemtamab, combined with Merck's Keytruda, showed a 50% reduction in death risk in a late-stage head and neck cancer trial. The study met both primary endpoints: overall survival and objective response rate. Genmab plans to engage regulators and present full results later. Analysts see potential upside, with an average price target of $94.89, implying 62% upside from recent levels.
How this was made
The 30-second read
Why it matters
The interim survival benefit is a material catalyst that can materially re‑rate the company's valuation and pipeline outlook.
Market read
The trial readout triggered a 30% stock surge, indicating immediate market impact and potential longer‑term upside.
What to watch
Regulatory timelines and competition from other PD‑L1 combos could limit upside despite the interim data.
Background
Genmab is a Danish biopharma known for royalty streams from partnered antibodies; the new data could create a wholly owned franchise.
Ticker impact
Genmab disclosed Phase 3 interim data showing a 50% reduction in death risk, sending the stock up 30% intraday.
likely upward pressure as investors price in potential approval and future sales
The hazard ratio of 0.50 and strong response odds are material clinical milestones that typically drive biotech stock rallies.
Market effects
Strengthens the head‑and‑neck cancer immunotherapy segment and may boost peers developing bispecific antibodies.
European biotech sentiment improves as a Danish firm shows breakthrough data.
Potentially raises interest in oncology pipelines worldwide.
Counterpoint
If the final analysis fails to confirm the interim benefit, the stock could face a sharp correction.
Key entities
- companyGenmab A/S
Danish biopharmaceutical company developing petosemtamab.
- companyMerck & Co.
Provider of Keytruda, partner in the combination therapy.
